Clinical Trial Update: Methyl Aminolevulinate 8% and 16% Incubated by 1 and 3 for Actinic Keratoses Treatment [NA]

View source ↗

Summary

Clinical trial update evaluating methyl aminolevulinate at 8% and 16% concentrations for actinic keratoses; the study status is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Actinic Keratoses

Drugs mentioned

• Methyl Aminolevulinate 16% (methyl aminolevulinate)
• Methyl Aminolevulinate 8% (methyl aminolevulinate)

Snippet

Sponsor: University of Nove de Julho | Conditions: Actinic Keratoses | NA | Status: NOT_YET_RECRUITING